ArticleTrials2026
Labelling of subpleural pulmonary nodules with blue dye and contrast agents under CT-guided control and subsequent video-assisted thoracoscopic resection: the BLUEPAT prospective randomised study.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundColour marking of indicated nodules is an innovative, accurate, and gentle method that allows subsequent wedge resection of the marked tissue using a mini-invasive, video-assisted thoracoscopic (VATS) method with all its benefits. One of the expected benefits of this clinical trial is introducing and optimising the evaluated way into routine management in diagnosing and treating focal lung diseases. The BLUEPAT clinical trial aims to assess the technique of colour marking of subpleural deposited small lung nodules with the subsequent performance of VATS wedge resection in surgical practice.
methodsThe BLUEPAT clinical trial is a prospective, monocentric, open-label, randomised study that will include 72 participants with subpleural deposited nodules with the need for additional histological diagnostics to optimise subsequent treatment. These patients will be randomised into two arms in a 1:1 ratio. The interventional arm will undergo VATS wedge resection of lung nodules marked with Patent Blue V and contrast agent iohexol under CT-guided control. The control arm will undergo VATS resection without prior colour coding of the lung nodules. The feasibility and safety of both methods will be assessed based on the evaluation of the parameters of the primary and secondary objectives of the study. The safety of the methods will be monitored by recording all related adverse events. All enrolled patients will undergo a 30-day follow-up period within the framework of clinical trial.
resultsThis article reports the clinical trial protocol; outcome data will be published upon study completion. DISCUSSION: The BLUEPAT clinical trial offers a novel assessment of this innovative approach for the diagnosis and treatment of focal lung diseases. The use of patent blue dye has been well established in diagnostic procedures for breast cancer and this study extends its potential application to pulmonary indications.
trial registrationEudraCT Number 2021-001122-22. Registered on March 18, 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.